14-05-2020
Jarun Ontakrai/ Shutterstock.com
Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Natera, Illumina, prenatal, testing, patent, infringement, licence, litigation, settle, agree, sequencing, platform, NPIT
Natera accuses CareDx of infringing DNA testing patents
17-05-2022
Invitae claims Natera infringed DNA patents
13-05-2021
Illumina to acquire Jeff Bezos-backed cancer testing company
23-09-2020
Teva to face inhaler infringement allegations in UK court
03-06-2020
Natera sues ArcherDX for oncology patent infringement
29-01-2020
English High Court upholds Sequenom patent for prenatal test
18-06-2019
